Literature DB >> 205686

Intraductal carcinoma. Long-term follow-up after treatment by biopsy alone.

W L Betsill, P P Rosen, P H Lieberman, G F Robbins.   

Abstract

A follow-up period averaging 21.6 years was obtained for patients with low-grade papillary intraductal carcinoma initially treated only by biopsy between 1940 and 1950. Subsequent carcinoma was diagnosed in the same breast in seven of the ten patients after an average interval of 9.7 years. Six of the seven subsequent carcinomas were invasive. Two of the patients died of metastatic carcinoma and two were known to be alive with metastases when last contacted. Three patients were without carcinoma following mastectomy. When these results were combined with the few reports available in the literature, it appeared that at least 39% of patients with intraductal carcinoma treated by biopsy alone subsequently had clinically evident carcinoma, invariably in the same breat, with an average latent period of about ten years. This was undoubtedly a result of the multicentric nature of the disease in many patients.

Entities:  

Mesh:

Year:  1978        PMID: 205686     DOI: 10.1001/jama.239.18.1863

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  56 in total

Review 1.  The p53 tumor suppressor gene in ductal carcinoma in situ of the breast.

Authors:  J F Simpson; D L Page
Journal:  Am J Pathol       Date:  2000-01       Impact factor: 4.307

2.  Screening for breast cancer: current status, problems, prospects.

Authors:  J E Devitt
Journal:  Can Fam Physician       Date:  1985-01       Impact factor: 3.275

3.  "Well, have I got cancer or haven't I?" The psycho-social issues for women diagnosed with ductal carcinoma in situ.

Authors:  Simone De Morgan; Sally Redman; Kate J White; Burcu Cakir; John Boyages
Journal:  Health Expect       Date:  2002-12       Impact factor: 3.377

4.  Silencing HoxA1 by intraductal injection of siRNA lipidoid nanoparticles prevents mammary tumor progression in mice.

Authors:  Amy Brock; Silva Krause; Hu Li; Marek Kowalski; Michael S Goldberg; James J Collins; Donald E Ingber
Journal:  Sci Transl Med       Date:  2014-01-01       Impact factor: 17.956

5.  Paget's disease of the nipple after subcutaneous mastectomy for cancer with primary reconstruction.

Authors:  C P Shearman; G T Watts
Journal:  Ann R Coll Surg Engl       Date:  1986-01       Impact factor: 1.891

6.  Natural history of in situ breast cancer in a defined population.

Authors:  W J Temple; M Jenkins; F Alexander; W S Hwang; L H Marx; A W Lees; H T Williams; M G Pambrun
Journal:  Ann Surg       Date:  1989-11       Impact factor: 12.969

7.  Can dedicated breast PET help to reduce overdiagnosis and overtreatment by differentiating between indolent and potentially aggressive ductal carcinoma in situ?

Authors:  Lucía Graña-López; Michel Herranz; Inés Domínguez-Prado; Sonia Argibay; Ángeles Villares; Manuel Vázquez-Caruncho
Journal:  Eur Radiol       Date:  2019-08-02       Impact factor: 5.315

Review 8.  Management of in situ and minimally invasive breast carcinoma.

Authors:  E R Frykberg; K I Bland
Journal:  World J Surg       Date:  1994 Jan-Feb       Impact factor: 3.352

Review 9.  Evaluation and management of high risk and premalignant lesions of the breast.

Authors:  D L Page; R A Jensen
Journal:  World J Surg       Date:  1994 Jan-Feb       Impact factor: 3.352

10.  Status of Intraductal Therapy for Ductal Carcinoma in Situ.

Authors:  Meghan Flanagan; Susan Love; E Shelley Hwang
Journal:  Curr Breast Cancer Rep       Date:  2010-05-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.